PMV Pharma reports PC14586 Phase 1 data: 32% ORR at high doses, responses in 6 tumor types

PMV Pharmaceuticals, Inc.

Overall response rate (ORR) 32% (8/25) in patients receiving daily dose ≥1150 mg; 24% (8/33) across all doses.
Partial responses observed in breast, endometrial, prostate, pancreatic, ovarian, and small cell lung cancers.
Maximum tolerated dose reached at 1500 mg twice daily; common AEs included nausea, vomiting, AST/ALT increases.
Phase 2 portion of PYNNACLE study expected to start early 2023; data provide proof of concept for p53 reactivation.
Data presented at ASCO 2022 by MD Anderson investigator; first-in-class small molecule targeting p53 Y220C mutation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.